pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-133a-1 |
Genomic Coordinates | chr18: 21825698 - 21825785 |
Synonyms | MIRN133A1, MIR133A1 |
Description | Homo sapiens miR-133a-1 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-133a-2 |
Genomic Coordinates | chr20: 62564912 - 62565013 |
Synonyms | MIRN133A2, MIR133A2 |
Description | Homo sapiens miR-133a-2 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-133a-3p | |||||||||||||||||||||||||||
Sequence | 53| UUUGGUCCCCUUCAACCAGCUG |74 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | RHOA | ||||||||||||||||||||
Synonyms | ARH12, ARHA, RHO12, RHOH12 | ||||||||||||||||||||
Description | ras homolog family member A | ||||||||||||||||||||
Transcript | NM_001664 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on RHOA | |||||||||||||||||||||
3'UTR of RHOA (miRNA target sites are highlighted) |
>RHOA|NM_001664|3'UTR 1 AACCTTGCTGCAAGCACAGCCCTTATGCGGTTAATTTTGAAGTGCTGTTTATTAATCTTAGTGTATGATTACTGGCCTTT 81 TTCATTTATCTATAATTTACCTAAGATTACAAATCAGAAGTCATCTTGCTACCAGTATTTAGAAGCCAACTATGATTATT 161 AACGATGTCCAACCCGTCTGGCCCACCAGGGTCCTTTTGACACTGCTCTAACAGCCCTCCTCTGCACTCCCACCTGACAC 241 ACCAGGCGCTAATTCAAGGAATTTCTTAACTTCTTGCTTCTTTCTAGAAAGAGAAACAGTTGGTAACTTTTGTGAATTAG 321 GCTGTAACTACTTTATAACTAACATGTCCTGCCTATTATCTGTCAGCTGCAAGGTACTCTGGTGAGTCACCACTTCAGGG 401 CTTTACTCCGTAACAGATTTTGTTGGCATAGCTCTGGGGTGGGCAGTTTTTTGAAAATGGGCTCAACCAGAAAAGCCCAA 481 GTTCATGCAGCTGTGGCAGAGTTACAGTTCTGTGGTTTCATGTTAGTTACCTTATAGTTACTGTGTAATTAGTGCCACTT 561 AATGTATGTTACCAAAAATAAATATATCTACCCCAGACTAGATGTAGTATTTTTTGTATAATTGGATTTCCTAATACTGT 641 CATCCTCAAAGAAAGTGTATTGGTTTTTTAAAAAAGAAAGTGTATTTGGAAATAAAGTCAGATGGAAAATTCATTTTTTA 721 AATTCCCGTTTTGTCACTTTTTCTGATAAAAGATGGCCATATTACCCCTTTTCGGCCCCATGTATCTCAGTACCCCATGG 801 AGCTGGGCTAAGTAAATAGGAATTGGTTTCACGCCTGAGGCAATTAGACACTTTGGAAGATGGCATAACCTGTCTCACCT 881 GGACTTAAGCATCTGGCTCTAATTCACAGTGCTCTTTTCTCCTCACTGTATCCAGGTTCCCTCCCAGAGGAGCCACCAGT 961 TCTCATGGGTGGCACTCAGTCTCTCTTCTCTCCAGCTGACTAAACTTTTTTTCTGTACCAGTTAATTTTTCCAACTACTA 1041 ATAGAATAAAGGCAGTTTTCTAAACTTCCTGTAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Care A; Catalucci D; Felicetti F; Bonci D; et al. - Nature medicine, 2007
Growing evidence indicates that microRNAs (miRNAs or miRs) are involved in basic cell functions and oncogenesis. Here we report that miR-133 has a critical role in determining cardiomyocyte hypertrophy. We observed decreased expression of both miR-133 and miR-1, which belong to the same transcriptional unit, in mouse and human models of cardiac hypertrophy. In vitro overexpression of miR-133 or miR-1 inhibited cardiac hypertrophy. In contrast, suppression of miR-133 by 'decoy' sequences induced hypertrophy, which was more pronounced than that after stimulation with conventional inducers of hypertrophy. In vivo inhibition of miR-133 by a single infusion of an antagomir caused marked and sustained cardiac hypertrophy. We identified specific targets of miR-133: RhoA, a GDP-GTP exchange protein regulating cardiac hypertrophy; Cdc42, a signal transduction kinase implicated in hypertrophy; and Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis. Our data show that miR-133, and possibly miR-1, are key regulators of cardiac hypertrophy, suggesting their therapeutic application in heart disease.
LinkOut: [PMID: 17468766]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Chiba Y; Tanabe M; Goto K; Sakai H; Misawa M - American journal of respiratory and critical care medicine, 2009
RATIONALE: Augmented bronchial smooth muscle (BSM) contraction is one of the causes of bronchial hyperresponsiveness. The protein RhoA and its downstream pathways have now been proposed as a new target for asthma therapy. MicroRNAs (miRNAs) play important roles in normal and diseased cell functions, and a contribution of miR-133 to RhoA expression has been suggested in cardiomyocytes. OBJECTIVES: To make clear the mechanism(s) of up-regulation of RhoA observed in the BSMs of experimental asthma, the role of miR-133a in RhoA expression was tested. METHODS: Total proteins and RNAs (containing miRNAs) were extracted from cultured human BSM cells (hBSMCs) that were treated with antagomirs and/or IL-13, and bronchial tissues of BALB/c mice that were sensitized and repeatedly challenged with ovalbumin. RhoA protein and miR-133a were detected by immunoblotting and quantified real-time reverse transcriptase-polymerase chain reaction, respectively. MEASUREMENTS AND MAIN RESULTS: In hBSMCs, an up-regulation of RhoA was observed when the function of endogenous miR-133a was inhibited by its antagomir. Treatment of hBSMCs with IL-13 caused an up-regulation of RhoA and a down-regulation of miR-133a. In bronchial tissues of the repeatedly ovalbumin-challenged mice, a significant increase in RhoA was observed. Interestingly, the level of miR-133a was significantly decreased in BSMs of the challenged mice. CONCLUSIONS: These findings suggest that RhoA expression is negatively regulated by miR-133a in BSMs. IL-13 might, at least in part, contribute to the reduction of miR-133a.
LinkOut: [PMID: 19644046]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
122 hsa-miR-133a-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000325 | RHOA | ras homolog family member A | 1 | 2 | ||||||||
MIRT000327 | CDC42 | cell division cycle 42 | 4 | 2 | ||||||||
MIRT000328 | ERG | ERG, ETS transcription factor | 1 | 1 | ||||||||
MIRT000329 | HCN4 | hyperpolarization activated cyclic nucleotide gated potassium channel 4 | 2 | 1 | ||||||||
MIRT000330 | UCP2 | uncoupling protein 2 | 2 | 2 | ||||||||
MIRT000331 | KRT7 | keratin 7 | 2 | 2 | ||||||||
MIRT001203 | CACNA1C | calcium voltage-gated channel subunit alpha1 C | 3 | 1 | ||||||||
MIRT001204 | HCN2 | hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 | 4 | 2 | ||||||||
MIRT001816 | PKM | pyruvate kinase, muscle | 1 | 1 | ||||||||
MIRT001986 | CASP9 | caspase 9 | 3 | 3 | ||||||||
MIRT002925 | KCNQ1 | potassium voltage-gated channel subfamily Q member 1 | 4 | 1 | ||||||||
MIRT003542 | FSCN1 | fascin actin-bundling protein 1 | 5 | 4 | ||||||||
MIRT004831 | KCNH2 | potassium voltage-gated channel subfamily H member 2 | 4 | 1 | ||||||||
MIRT005604 | TAGLN2 | transgelin 2 | 5 | 4 | ||||||||
MIRT005813 | LASP1 | LIM and SH3 protein 1 | 3 | 2 | ||||||||
MIRT006571 | PNP | purine nucleoside phosphorylase | 4 | 2 | ||||||||
MIRT006680 | MSN | moesin | 2 | 1 | ||||||||
MIRT007032 | EGFR | epidermal growth factor receptor | 3 | 5 | ||||||||
MIRT007088 | VKORC1 | vitamin K epoxide reductase complex subunit 1 | 1 | 1 | ||||||||
MIRT007383 | PRDM16 | PR/SET domain 16 | 1 | 2 | ||||||||
MIRT021693 | TPM1 | tropomyosin 1 | 1 | 1 | ||||||||
MIRT021695 | FBN1 | fibrillin 1 | 1 | 1 | ||||||||
MIRT021696 | FAM120C | family with sequence similarity 120C | 1 | 1 | ||||||||
MIRT021697 | BCAN | brevican | 1 | 1 | ||||||||
MIRT021698 | TCTEX1D2 | Tctex1 domain containing 2 | 1 | 1 | ||||||||
MIRT021699 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 1 | 1 | ||||||||
MIRT021700 | RFT1 | RFT1 homolog | 1 | 1 | ||||||||
MIRT021701 | SENP1 | SUMO1/sentrin specific peptidase 1 | 1 | 1 | ||||||||
MIRT021702 | SMIM14 | small integral membrane protein 14 | 1 | 1 | ||||||||
MIRT021703 | PRELID1 | PRELI domain containing 1 | 1 | 1 | ||||||||
MIRT021704 | CNN2 | calponin 2 | 3 | 3 | ||||||||
MIRT021705 | ARPC5 | actin related protein 2/3 complex subunit 5 | 4 | 2 | ||||||||
MIRT021706 | FTL | ferritin light chain | 2 | 2 | ||||||||
MIRT021707 | CERS2 | ceramide synthase 2 | 1 | 1 | ||||||||
MIRT021708 | SEC61B | Sec61 translocon beta subunit | 1 | 1 | ||||||||
MIRT021709 | PLEKHA3 | pleckstrin homology domain containing A3 | 1 | 1 | ||||||||
MIRT021710 | EGFL7 | EGF like domain multiple 7 | 1 | 1 | ||||||||
MIRT021711 | VEGFA | vascular endothelial growth factor A | 1 | 1 | ||||||||
MIRT021712 | PIK3R2 | phosphoinositide-3-kinase regulatory subunit 2 | 1 | 1 | ||||||||
MIRT021713 | RGS3 | regulator of G protein signaling 3 | 1 | 1 | ||||||||
MIRT021714 | COL1A1 | collagen type I alpha 1 chain | 4 | 1 | ||||||||
MIRT021715 | GSTP1 | glutathione S-transferase pi 1 | 2 | 1 | ||||||||
MIRT035537 | SP1 | Sp1 transcription factor | 2 | 2 | ||||||||
MIRT035579 | KLF15 | Kruppel like factor 15 | 1 | 1 | ||||||||
MIRT045837 | NR4A2 | nuclear receptor subfamily 4 group A member 2 | 1 | 1 | ||||||||
MIRT052647 | BCL2L1 | BCL2 like 1 | 4 | 2 | ||||||||
MIRT052648 | MCL1 | MCL1, BCL2 family apoptosis regulator | 4 | 2 | ||||||||
MIRT053333 | RFFL | ring finger and FYVE like domain containing E3 ubiquitin protein ligase | 4 | 1 | ||||||||
MIRT054310 | IGF1R | insulin like growth factor 1 receptor | 3 | 2 | ||||||||
MIRT055599 | FAM160B1 | family with sequence similarity 160 member B1 | 2 | 2 | ||||||||
MIRT081957 | UBA2 | ubiquitin like modifier activating enzyme 2 | 4 | 1 | ||||||||
MIRT437400 | MMP14 | matrix metallopeptidase 14 | 3 | 1 | ||||||||
MIRT437953 | ANXA2 | annexin A2 | 4 | 1 | ||||||||
MIRT437954 | SNX30 | sorting nexin family member 30 | 4 | 1 | ||||||||
MIRT437955 | SGMS2 | sphingomyelin synthase 2 | 4 | 1 | ||||||||
MIRT438719 | PDLIM5 | PDZ and LIM domain 5 | 3 | 1 | ||||||||
MIRT452802 | PACS2 | phosphofurin acidic cluster sorting protein 2 | 2 | 2 | ||||||||
MIRT462823 | BCL3 | B-cell CLL/lymphoma 3 | 2 | 2 | ||||||||
MIRT468494 | SESN2 | sestrin 2 | 2 | 2 | ||||||||
MIRT477714 | EFHD2 | EF-hand domain family member D2 | 2 | 2 | ||||||||
MIRT483852 | EMID1 | EMI domain containing 1 | 2 | 2 | ||||||||
MIRT490039 | PRRT2 | proline rich transmembrane protein 2 | 2 | 2 | ||||||||
MIRT491349 | CDKN1A | cyclin dependent kinase inhibitor 1A | 2 | 4 | ||||||||
MIRT504443 | MC2R | melanocortin 2 receptor | 2 | 2 | ||||||||
MIRT505701 | SESN3 | sestrin 3 | 2 | 2 | ||||||||
MIRT513521 | RHOQ | ras homolog family member Q | 2 | 4 | ||||||||
MIRT517423 | HIST2H2AC | histone cluster 2 H2A family member c | 2 | 2 | ||||||||
MIRT526599 | DCAKD | dephospho-CoA kinase domain containing | 2 | 2 | ||||||||
MIRT528904 | THBS2 | thrombospondin 2 | 2 | 2 | ||||||||
MIRT533060 | ZBTB37 | zinc finger and BTB domain containing 37 | 2 | 2 | ||||||||
MIRT534126 | SNX33 | sorting nexin 33 | 2 | 2 | ||||||||
MIRT534700 | RNF103-CHMP3 | RNF103-CHMP3 readthrough | 2 | 4 | ||||||||
MIRT535732 | MYPN | myopalladin | 2 | 2 | ||||||||
MIRT538529 | CHMP3 | charged multivesicular body protein 3 | 2 | 4 | ||||||||
MIRT550878 | IBA57 | IBA57 homolog, iron-sulfur cluster assembly | 2 | 2 | ||||||||
MIRT551260 | PSMG1 | proteasome assembly chaperone 1 | 2 | 2 | ||||||||
MIRT551981 | UGT2B10 | UDP glucuronosyltransferase family 2 member B10 | 2 | 2 | ||||||||
MIRT553866 | SYAP1 | synapse associated protein 1 | 2 | 2 | ||||||||
MIRT558810 | CDK5R1 | cyclin dependent kinase 5 regulatory subunit 1 | 2 | 2 | ||||||||
MIRT559367 | ATP13A3 | ATPase 13A3 | 2 | 2 | ||||||||
MIRT560941 | ZFP28 | ZFP28 zinc finger protein | 2 | 2 | ||||||||
MIRT565461 | SUPT16H | SPT16 homolog, facilitates chromatin remodeling subunit | 2 | 2 | ||||||||
MIRT566234 | PTMA | prothymosin, alpha | 2 | 2 | ||||||||
MIRT568217 | C11orf24 | chromosome 11 open reading frame 24 | 2 | 2 | ||||||||
MIRT608912 | NCDN | neurochondrin | 2 | 6 | ||||||||
MIRT613229 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT623563 | ITPKB | inositol-trisphosphate 3-kinase B | 2 | 2 | ||||||||
MIRT637224 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT641669 | CCNI | cyclin I | 2 | 2 | ||||||||
MIRT644440 | ALDOC | aldolase, fructose-bisphosphate C | 2 | 2 | ||||||||
MIRT644755 | TXNRD3NB | thioredoxin reductase 3 neighbor | 2 | 2 | ||||||||
MIRT646711 | PDE1A | phosphodiesterase 1A | 2 | 2 | ||||||||
MIRT647577 | RBMXL1 | RNA binding motif protein, X-linked like 1 | 2 | 2 | ||||||||
MIRT647760 | RNF168 | ring finger protein 168 | 2 | 2 | ||||||||
MIRT649267 | C17orf64 | chromosome 17 open reading frame 64 | 2 | 2 | ||||||||
MIRT651238 | ZMAT4 | zinc finger matrin-type 4 | 2 | 2 | ||||||||
MIRT652146 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT657168 | IP6K1 | inositol hexakisphosphate kinase 1 | 2 | 2 | ||||||||
MIRT668302 | FOSL2 | FOS like 2, AP-1 transcription factor subunit | 2 | 2 | ||||||||
MIRT687546 | MLEC | malectin | 2 | 2 | ||||||||
MIRT690857 | PLEKHG2 | pleckstrin homology and RhoGEF domain containing G2 | 2 | 2 | ||||||||
MIRT697060 | PSMC4 | proteasome 26S subunit, ATPase 4 | 2 | 2 | ||||||||
MIRT699725 | SERPINH1 | serpin family H member 1 | 2 | 2 | ||||||||
MIRT700858 | PER2 | period circadian clock 2 | 2 | 2 | ||||||||
MIRT705068 | C4orf29 | abhydrolase domain containing 18 | 2 | 2 | ||||||||
MIRT709496 | ANGPT4 | angiopoietin 4 | 2 | 2 | ||||||||
MIRT713925 | PIGR | polymeric immunoglobulin receptor | 2 | 2 | ||||||||
MIRT716058 | SFTPB | surfactant protein B | 2 | 2 | ||||||||
MIRT716724 | APOL6 | apolipoprotein L6 | 2 | 2 | ||||||||
MIRT721677 | CMTM4 | CKLF like MARVEL transmembrane domain containing 4 | 2 | 2 | ||||||||
MIRT723379 | NFAM1 | NFAT activating protein with ITAM motif 1 | 2 | 2 | ||||||||
MIRT731340 | IGF1 | insulin like growth factor 1 | 1 | 1 | ||||||||
MIRT731591 | ZEB1 | zinc finger E-box binding homeobox 1 | 1 | 1 | ||||||||
MIRT732526 | PTBP1 | polypyrimidine tract binding protein 1 | 2 | 0 | ||||||||
MIRT732527 | KDM5C | lysine demethylase 5C | 2 | 0 | ||||||||
MIRT732589 | BCL2 | BCL2, apoptosis regulator | 2 | 0 | ||||||||
MIRT732590 | CASP3 | caspase 3 | 2 | 0 | ||||||||
MIRT733594 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 3 | 0 | ||||||||
MIRT735355 | MB | myoglobin | 1 | 0 | ||||||||
MIRT735744 | CDCA8 | cell division cycle associated 8 | 3 | 0 | ||||||||
MIRT736984 | SET | SET nuclear proto-oncogene | 1 | 0 | ||||||||
MIRT737550 | TGFB1 | transforming growth factor beta 1 | 4 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|